RxDoctor Payments Data

Andrew Sher, MD

Urology · Oxford, FLNPI 1730155672

Payments from drug & device makers

$15,734in general payments, 2019–2025

Across 284 payments — averaging $55.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Laser Specialty Medical, LLC$10K
  • Bayer$698
  • Johnson & Johnson$589
  • Sumitomo Pharma America, Inc.$527
  • Pfizer$385
  • AbbVie$314
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$5,91238%
  • Education$3222%
  • Ownership interest$9,50060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,734 in reported general payments places this provider in the 80th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$982,819
Medicare patients
2,038
Services billed
33,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide178$2,485,634
ErleadaApalutamide41$711,945
OrgovyxRelugolix105$278,577
NubeqaDarolutamide21$266,879
MyrbetriqMirabegron199$229,755
GemtesaVibegron45$57,693
ElmironPentosan Polysulfate Sodium20$31,229
Tamsulosin Hcl1,428$23,722
Finasteride1,275$20,346
Dutasteride424$15,327
Abiraterone Acetate13$14,205
Solifenacin Succinate146$13,960
Alfuzosin Hcl ErAlfuzosin Hcl444$12,438
Tolterodine Tartrate ErTolterodine Tartrate82$11,945
Tadalafil121$10,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$265$2,715,389377 claims
Johnson & JohnsonErleada$589$711,94541 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$527$336,271150 claims
BayerNubeqa$698$266,87921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 urology providers in Florida.

Other urology in Oxford

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →